07:44 AM EDT, 09/30/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) said Tuesday it has priced the underwritten offering of more than 37.9 million common shares at $12.53 per share, for gross proceeds of $475 million before fees and expenses.

The offering is expected to close on or about Oct. 1, subject to customary closing conditions, the biopharmaceutical company said.

Ocular Therapeutix ( OCUL ) plans to use the proceeds from the offering, along with existing cash and cash equivalents, to fund its planned open-label extension study for Axpaxli in patients with wet age-related macular degeneration, as well as the planned phase 3 clinical trials of Axpaxli for the treatment of non-proliferative diabetic retinopathy.

Part of the proceeds will also be used for investments in infrastructure, pre-commercialization activities related to Axpaxli, and for working capital and other general corporate purposes, the company said.